NASDAQ:KOD Kodiak Sciences (KOD) Stock Price, News & Analysis $87.90 +0.18 (+0.21%) As of 09:48 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Kodiak Sciences Stock (NASDAQ:KOD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kodiak Sciences alerts:Sign Up Key Stats Today's Range$87.18▼$87.1850-Day Range$31.52▼$99.8752-Week Range$15.83▼$104.00Volume23,732 shsAverage Volume1.14 million shsMarket Capitalization$5.52 billionP/E RatioN/ADividend YieldN/APrice Target$104.71Consensus RatingModerate Buy Company Overview Kodiak Sciences Inc. (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company’s research centers on therapies designed to address conditions that can cause vision loss, including diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion. Kodiak’s proprietary Antibody Biopolymer Conjugate platform is designed to combine the targeting capabilities of antibody-based medicines with a biodegradable polymer intended to extend the duration of treatment in the eye. Its lead investigational program, tarcocimab tedromer (KSI-301), is an anti-vascular endothelial growth factor therapy developed for several retinal vascular diseases. Kodiak has also investigated additional ophthalmic candidates and combination approaches using the platform. Founded in 2015 and headquartered in Palo Alto, California, Kodiak has conducted clinical development activities in the United States and international markets. The company’s therapies remain investigational, and its business is centered on research and clinical development rather than commercial products. Victor Perlroth, M.D., is the company’s co-founder and chief executive officer.AI Generated. May Contain Errors. Read More Kodiak Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreKOD MarketRank™: 4.09133271202 of 5 starsKodiak Sciences scored higher than 82% of companies evaluated by MarketBeat, and ranked 105th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingKodiak Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialKodiak Sciences has a consensus price target of $104.71, representing about 19.7% upside from its current price of $87.50.Amount of Analyst CoverageKodiak Sciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kodiak Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kodiak Sciences are expected to decrease in the coming year, from ($3.97) to ($4.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kodiak Sciences is -20.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kodiak Sciences is -20.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKodiak Sciences has a P/B Ratio of 29.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kodiak Sciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted26.83% of the float of Kodiak Sciences has been sold short.Short Interest Ratio / Days to CoverKodiak Sciences has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kodiak Sciences has recently decreased by 12.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKodiak Sciences does not currently pay a dividend.Dividend GrowthKodiak Sciences does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.68 News SentimentKodiak Sciences has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kodiak Sciences this week, compared to 5 articles on an average week.Search Interest22 people have searched for KOD on MarketBeat in the last 30 days. This is an increase of 340% compared to the previous 30 days.MarketBeat Follows10 people have added Kodiak Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $156,986,026.00 in company stock, which represents 2.8546% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Kodiak Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $156,986,026.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders44.40% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.06% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kodiak Sciences' insider trading history. Receive KOD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KOD Stock News HeadlinesKodiak Sciences Inc. (KOD) - What Are Investment Firms Saying About This Stock?October 18, 2026 | americanbankingnews.comHC Wainwright Expects Increased Earnings for Kodiak SciencesOctober 16, 2026 | americanbankingnews.comFox News: Wall Street Can Seize Your RetirementFox News reported that under current law, legal title to most stocks and bonds sits with a central institution, Cede and Company, not the individual investor. If a brokerage collapses and customer securities were pledged as collateral, secured creditors can legally come before account holders. Physical gold held in a self-directed IRA is registered directly to you, with no clearinghouse or central institution holding its title.October 22 at 1:00 AM | Monetary Gold (Ad)HC Wainwright Comments on Kodiak Sciences FY2030 EarningsOctober 15, 2026 | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Kodiak Sciences (KOD), Newron Pharmaceuticals SpA (OtherNWPHF) and Illumina (ILMN)October 13, 2026 | theglobeandmail.comKodiak Sciences Inc. (KOD) Presents at American Academy of Ophthalmology Conference 2026 - SlideshowOctober 10, 2026 | seekingalpha.comKodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial NewsOctober 9, 2026 | finance.yahoo.comKodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data UpdateOctober 8, 2026 | finance.yahoo.comSee More Headlines KOD Stock Analysis - Frequently Asked Questions How have KOD shares performed this year? Kodiak Sciences' stock was trading at $27.96 at the beginning of 2026. Since then, KOD shares have increased by 212.9% and is now trading at $87.4990. How were Kodiak Sciences' earnings last quarter? Kodiak Sciences Inc. (NASDAQ:KOD) announced its earnings results on Thursday, August, 13th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.96) by $0.09. When did Kodiak Sciences IPO? Kodiak Sciences (KOD) raised $126 million in an IPO on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays and Chardan were co-managers. Who are Kodiak Sciences' major shareholders? Kodiak Sciences' top institutional investors include Abel Hall LLC (0.01%), JGP Global Gestao de Recursos Ltda. (0.01%) and Nisa Investment Advisors LLC. Insiders that own company stock include Bros Advisors Lp Baker and John A Borgeson. View institutional ownership trends. How do I buy shares of Kodiak Sciences? Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kodiak Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kodiak Sciences investors own include NVIDIA (NVDA), Tesla (TSLA), Micron Technology (MU), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Marvell Technology (MRVL) and Rocket Lab (RKLB). Company Calendar Last Earnings8/13/2026Today10/22/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (18m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 KOD's financial health is in the Green zone, according to TradeSmith. KOD has been in this zone for over 18 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KOD CIK1468748 Webkodiak.com Phone(650) 281-0850FaxN/AEmployees124Year Founded2009Price Target and Rating Average Price Target for Kodiak Sciences$104.71 High Price Target$145.00 Low Price Target$61.00 Potential Upside/Downside+19.4%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($4.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$229.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-273.23% Return on Assets-85.48% Debt Debt-to-Equity RatioN/A Current Ratio2.49 Quick Ratio2.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book29.54Miscellaneous Outstanding Shares62,850,000Free Float34,944,000Market Cap$5.51 billion OptionableOptionable Beta2.03 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:KOD) was last updated on 10/22/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | Sponsored80 Days Until the Pentagon Restricts Chinese Rare EarthsChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kodiak Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kodiak Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
